Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone for Idiopathic Sudden Sensorineural Hearing Loss (ECOSUB)
NCT07067801Phase 3Not yet recruiting
- Sponsor
- CHU de Besançon
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prednisone in idiopathic sudden sensorineural hearing loss (ISSNHL) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Early hearing recovery at 10 days. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
prednisone
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on NCT07067801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07067801.